• ProMIS Neurosciences (PMN) will participate in the 2020 BIO CEO & Investor Conference in New York.
  • The company’s Executive Chairman, Eugene Williams, will give a presentation during the conference.
  • Mr Williams will present data which supports the company’s antibody program for neurodegenerative diseases.
  • ProMIS’s share price remains unchanged, with shares trading at $0.22 apiece.

Biotechnology company ProMIS Neurosciences (PMN) will send a representative to attend and participate in the 2020 BIO CEO & Investor Conference.

The 2-day long conference will be hosted at the Marriott Marquis Hotel in New York City.

The event will bring together investors, industry analysts, and senior executives from biotechnology and pharmaceutical companies like ProMIS.

The conference will take place on February 10th and 11th, with company presentations on both days.

The Executive Chairman of ProMIS, Eugene Williams, will give a presentation at 3:00pm (Eastern Time) on February 11th.

In his presentation, Mr Williams will present data that supports ProMIS’ antibody programs for targeting and treating neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and ALS.

Unfortunately, webcasting will not be available for the event.

ProMIS’s share price remains unchanged, with shares trading at $0.22 apiece.

More From The Market Online
WELL Health founder and CEO Hamed Shahbazi, centre.

WELL subsidiary launches support for women’s hormonal imbalance

WELL Health (TSX:WELL) subsidiary Wisp, the United States' largest dedicated women's telehealth provider, launches a weight care vertical.
Stock image generated with AI

Buzz on the Bullboards: Stocks to watch as TSX hits new highs

The TSX experienced a roller-coaster of wins and losses this week, yet managed to break a record high with three companies standing out.
AI healthcare technology

The 10 best AI healthcare stocks to watch

Read about the strong contingent of healthcare stocks keen on applying AI technology to improve patient outcomes.
image of scientist looking into a microscope

BriaCell Therapeutics advances Phase 3 MBC clinical study

BriaCell Therapeutics (TSX:BCT) advances its Phase 3 study of Bria-IMT patients with metastatic breast cancer.